Anavex Life Sciences (AVXL) PT Set at $10.00 by Roth Capital
Anavex Life Sciences (NASDAQ:AVXL) received a $10.00 price objective from equities researchers at Roth Capital in a research report issued to clients and investors on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s price objective points to a potential upside of 325.53% from the company’s current price.
Several other research analysts also recently commented on AVXL. Maxim Group set a $7.00 price objective on shares of Anavex Life Sciences and gave the company a “buy” rating in a research report on Friday, October 19th. HC Wainwright set a $10.00 price objective on shares of Anavex Life Sciences and gave the company a “buy” rating in a research report on Wednesday, October 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $7.40.
NASDAQ AVXL opened at $2.35 on Friday. Anavex Life Sciences has a 1-year low of $1.25 and a 1-year high of $4.35. The company has a market capitalization of $95.65 million, a PE ratio of -6.03 and a beta of 2.41.
Institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC acquired a new position in Anavex Life Sciences during the second quarter valued at approximately $1,749,000. Jane Street Group LLC acquired a new position in Anavex Life Sciences during the second quarter valued at approximately $157,000. Finally, Hikari Power Ltd acquired a new position in Anavex Life Sciences during the fourth quarter valued at approximately $231,000. Institutional investors and hedge funds own 17.88% of the company’s stock.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
See Also: Short Selling
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.